This invention relates to expandable endoprosthesis devices, generally called stents, which are adapted to be implanted into a patient's body lumen, such as blood vessel, to maintain the patency thereof. These devices are very useful in the treatment of atherosclerotic stenosis in blood vessels.
Various means have been described to deliver and implant stents. One method frequently described for delivering a stent to a desired intraluminal location includes mounting the expandable stent on an expandable member, such as a balloon, provided on the distal end of an intravascular catheter, advancing the catheter to the desired location within the patient's body lumen, inflating the balloon on the catheter to expand the stent into a permanent expanded condition and then deflating the balloon and removing the catheter.
The stent must be able to satisfy a number of mechanical requirements. First, the stent must be capable of withstanding the structural loads, namely radial compressive forces, imposed on the stent as it supports the wall of a vessel. Therefore, a stent must possess adequate radial strength. Radial strength, which is the ability of a stent to resist radial compressive forces, is due to strength and rigidity around the circumferential direction of the stent. Radial strength and rigidity, therefore, may also be described as, hoop or circumferential strength and rigidity.
Once expanded, the stent must adequately maintain its size and shape throughout its service life despite the various forces that may come to bear on it, including the cyclic loading induced by the beating heart. For example, a radially directed force may tend to cause a stent to recoil inward. Generally, it is desirable to minimize recoil.
In addition, the stent must possess sufficient flexibility to allow for crimping, expansion, and cyclic loading. Longitudinal flexibility is important to allow the stent to be maneuvered through a tortuous vascular path and to enable it to conform to a deployment site that may not be linear or may be subject to flexure. Finally, the stent must be biocompatible so as not to trigger any adverse vascular responses.
The structure of a stent is typically composed of scaffolding that includes a pattern or network of interconnecting structural elements. The scaffolding can be formed from wires, tubes, or sheets of material rolled into a cylindrical shape. The scaffolding is designed so that the stent can be radially compressed (to allow crimping) and radially expanded (to allow deployment). A conventional stent is allowed to expand and contract through movement of individual structural elements of a pattern with respect to each other.
Additionally, a medicated stent may be fabricated by coating the surface of either a metallic or polymeric scaffolding with a polymeric carrier that includes an active or bioactive agent or drug. Polymeric scaffolding may also serve as a carrier of an active agent or drug.
Furthermore, it may be desirable for a stent to be biodegradable. In many treatment applications, the presence of a stent in a body may be necessary for a limited period of time until its intended function of, for example, maintaining vascular patency and/or drug delivery is accomplished. Therefore, stents fabricated from biodegradable, bioabsorbable, and/or bioerodable materials such as bioabsorbable polymers should be configured to completely erode only after the clinical need for them has ended.
Along with crimping and expansion forces, implanting a stent in the dynamic environment in a curved artery section causes stresses in the stent structure that can result in fatigue failure. This fatigue failure is particularly acute in stents formed from a polymer material.
What has been needed and heretofore unavailable is a stent formed from a polymer material and modified in critical structural areas where cyclical loads are concentrated, and fatigue stresses are constant in order to improve the fatigue performance of the stent.
The present invention is directed to an expandable stent which is relatively flexible along its longitudinal axis to facilitate delivery through tortuous body lumens, but which has structural features to improve fatigue performance of the stent.
The stent of the invention generally includes a plurality of radially expandable cylindrical elements or rings which are relatively independent in their ability to expand and to flex relative to one another. Interconnecting elements or links extending between adjacent cylindrical rings provide increased stability and prevent warping of the stent upon the expansion thereof. The resulting stent structure is a series of radially expandable cylindrical rings which are spaced longitudinally close enough so that small dissections in the wall of a body lumen may be pressed back into position against the lumenal wall, but not so close as to compromise the longitudinal flexibility of the stent.
Each of the cylindrical rings making up the stent has a proximal end and a distal end and a cylindrical plane defined by a cylindrical outer wall surface that extends circumferentially between the proximal end and the distal end of the cylindrical ring. Generally the cylindrical rings have a serpentine or undulating shape which includes at least one U-shaped element, and typically each ring has more than one U-shaped element. The cylindrical rings are interconnected by at least one link which attaches one cylindrical ring to an adjacent cylindrical ring. The combination of the rings and links allows the stent to be highly flexible along its longitudinal axis.
Not only do the links that interconnect the cylindrical rings provide flexibility to the stent, but the positioning of the links also enhances the flexibility by allowing uniform flexibility when the stent is bent in any direction along its longitudinal axis. Uniform flexibility along the stent derives in part from the links of one ring being circumferentially offset from the links in an adjacent ring. Further, the cylindrical rings are configured to provide flexibility to the stent in that portions of the rings can flex or bend as the stent is delivered through a tortuous vessel.
The cylindrical rings typically are formed of a plurality of peaks and valleys, where the valleys of one cylindrical ring are in phase with the valleys of an adjacent cylindrical ring. In this configuration, at least one link attaches each cylindrical ring to an adjacent cylindrical ring so that at least a portion of the link is positioned within one of the valleys and it attaches the valley to an adjacent peak.
While the cylindrical rings and links generally are not separate structures, they have been conveniently referred to as rings and links for ease of identification. Further, the cylindrical rings can be thought of as comprising a series of U's, W's and Y-shaped structures in a repeating pattern. Again, while the cylindrical rings are not divided up or segmented into U's, W's and Y's, the pattern of the cylindrical rings resemble such configurations. The U's, W's and Y's promote flexibility in the stent primarily by flexing as the stent is delivered through a tortuous vessel.
The radial expansion of the expandable ring deforms the undulating pattern thereof similar to changes in a waveform which result in decreasing the waveform's amplitude. Preferably, the undulating patterns of the individual cylindrical structures are in phase with each other in order to prevent the contraction of the stent along its length when it is expanded. The cylindrical structures of the stent are plastically deformed when expanded (except with NiTi alloys) so that the stent will remain in the expanded condition, therefore they must be sufficiently rigid when expanded to prevent the collapse thereof in use.
The links which interconnect adjacent cylindrical rings should have a transverse cross-section similar to the transverse dimensions of the undulating components of the expandable cylindrical rings. The links may be formed in a unitary structure with the expandable cylindrical rings from the same intermediate product, such as a tubular element. Preferably, all of the links of a stent are joined at either the peaks or the valleys of the undulating structure of the cylindrical rings which form the stent. In this manner, there is no shortening of the stent upon expansion.
The number and location of the links interconnecting adjacent cylindrical rings can be varied in order to develop the desired longitudinal flexibility in the stent structure both in the unexpanded as well as the expanded condition. These properties are important to minimize alteration of the natural physiology of the body lumen into which the stent is implanted and to maintain the compliance of the body lumen which is internally supported by the stent. Generally, the greater the longitudinal flexibility of the stent, the easier and the more safely it can be delivered to the implantation site.
In one embodiment, the Y-shaped members are formed by the link attaching to a curved portion of a valley, which then resembles the Y-shaped member. In this embodiment, there is a gradual radius on each side of the link where it connects to the curved portion of the Y-shaped member. More specifically, a smooth and gradual transition radius extends from each side of the link to the curved portion of the Y-shaped member, the radius being in the range from 0.017 to 0.022 inch (0.44 to 0.55 mm). One preferred radius is 0.019 inch (0.50 mm). These gradual and smooth transition radii provide a more ridged and stiffer scaffold area resulting in improved link structural fatigue performance.
In another embodiment, the Y-shaped members are formed by the links attaching to a curved portion of a valley, which then resembles the Y-shaped member. In this embodiment, the curved portion of the valley has a width that is less than the width of the curved portion of the peaks forming the U-shaped members. In one embodiment, the width of the curved portion of the valley of the Y-shaped member is in the range from 0.0073 to 0.0066 inch (0.185 to 0.168 mm). In one preferred embodiment, the width of the curved portion of the valley of the Y-shaped member is 0.0068 inch (0.173 mm). This Y-shaped member provides a reduced width which will experience less stress during fatigue loading, and hence result in improved Y-shaped member structural fatigue performance.
In another embodiment, the Y-shaped members are formed by the links attaching to a curved portion of a valley, which then resembles the Y-shaped member. In this embodiment, relief dimples are formed in the curved portion of the valley where the link attaches to the curved portion. Link fatigue factures can occur at the end of a straight strut segment near the link and valley junction where the material is highly stressed during fatigue loading and fatigue strength is lower due to the axially oriented material being weaker. The purpose of introducing relief dimples on the curved portion of the valley is to shift the location of this highly stressed area more into the curved portion of the valley where the circumferentially oriented material is stronger and can withstand more stress, thereby improving structural fatigue performance.
Other features and advantages of the present invention will become more apparent from the following detailed description of the invention, when taken in conjunction with the accompanying exemplary drawings.
The delivery catheter 11, onto which the stent 10 is mounted, is similar to a conventional balloon dilatation catheter used for angioplasty procedures.
Each radially expandable cylindrical ring 12 of the stent 10 may be independently expanded. Therefore, the balloon 14 may be provided with an inflated shape other than cylindrical, e.g. tapered, to facilitate implantation of the stent 10 in a variety of body lumen shapes.
The delivery of the stent 10 is accomplished in the following manner. The stent 10 is first mounted onto the inflatable balloon 14 on the distal extremity of the delivery catheter 11. The balloon 14 is slightly inflated to secure the stent 10 onto the exterior of the balloon. The catheter-stent assembly is introduced within the patient's vasculature in a conventional Seldinger technique through a guiding catheter (not shown). A guidewire 18 is disposed across an arterial section and then the catheter-stent assembly is advanced over a guidewire 18 within the artery 15 until the stent 10 is positioned in the area to be repaired. The balloon 14 of the catheter 11 is expanding the stent 10 against the artery 15, which is illustrated in
The stent 10 serves to hold open the artery 15 after the catheter 11 is withdrawn, as illustrated by
The properties of the stent 10 may also be varied by alteration of the undulating pattern of the cylindrical rings 12.
The number of undulations may also be varied to accommodate placement of links 13, e.g., at the peaks of the undulations as shown in
As shown in
The underlying structure or substrate of a stent can be completely or at least in part made from a biodegradable polymer or combination of biodegradable polymers, a biostable polymer or combination of biostable polymers, or a combination of biodegradable and biostable polymers. Additionally, a polymer-based coating for a surface of a device can be a biodegradable polymer or combination of biodegradable polymers, a biostable polymer or combination of biostable polymers, or a combination of biodegradable and biostable polymers.
A stent may be fabricated from a polymeric tube or a sheet by rolling and bonding the edges to form a tube. A stent pattern may be formed on a polymeric tube by laser cutting a pattern on the tube. Representative examples of lasers that may be used include, but are not limited to, excimer, carbon dioxide, and YAG. In other embodiments, chemical etching may be used to form a pattern on a tube.
The pattern of a stent can vary throughout its structure to allow radial expansion and compression and longitudinal flexure. A pattern may include portions of struts that are straight or relatively straight, or some patterns may include bending elements. The bending elements can comprise free bending elements, W-shaped bending elements, and Y-shaped bending elements. Bending elements that have a U-shape are free bending elements. The free bending elements are not directly connected to any adjacent ring, whereas each W-shaped bending element is directly connected by one of the links at a concave portion of the apex of the W-shaped bending element to a convex portion of an apex on an adjacent ring located in a direction of a first end of a scaffold, and each Y-shaped bending element is directly connected by one of the links at a convex portion of the apex of the Y-shaped bending element to a concave portion of an apex on an adjacent ring located in a direction of a second end of the scaffold.
Bending elements bend inward when a stent is crimped to allow radial compression. Bending elements also bend outward when a stent is expanded to allow for radial expansion. After deployment, a stent is under static and cyclic compressive loads from the vessel walls. Thus, bending elements are subjected to deformation during use. “Use” includes, but is not limited to, manufacturing, assembling (e.g., crimping stent on a catheter), delivery of stent into and through a bodily lumen to a treatment site, and deployment of stent at a treatment site, and treatment after deployment.
As indicated above, a stent has certain mechanical requirements. A stent must have sufficient radial strength to withstand structural loads, namely radial compressive forces, imposed on the stent as it supports the walls of a vessel. In addition, the stent must possess sufficient flexibility to allow for crimping, expansion, and cyclic loading. Also, a sufficiently low profile is important to deliver the stent to the treatment site.
Polymers tend to have a number of shortcomings for use as materials for stents. One such shortcoming is that many biodegradable polymers have a relatively low modulus, and thus relatively low radial strength. Compared to metals, the strength to weight ratio of polymers is smaller than that of metals. A polymeric stent with inadequate radial strength can result in mechanical failure or recoil inward after implantation into a vessel. To compensate for the relatively low modulus, a polymeric stent requires significantly thicker struts than a metallic stent, which results in an undesirably large profile.
Another shortcoming of polymers is that many polymers, such as biodegradable polymers, tend to be brittle under physiological conditions or conditions within a human body. Specifically, such polymers can have a Tg, which is defined below, above human body temperature which is approximately 37° C. These polymer systems exhibit a brittle fracture mechanism in which there is little or no plastic deformation prior to failure. As a result, a stent fabricated from such polymers can have insufficient toughness for the range of use of a stent. In particular, it is important for a stent to be resistant to fracture throughout the range of use of a stent, i.e., crimping, delivery, deployment, and during a desired treatment period.
The “glass transition temperature,” Tg, is the temperature at which the amorphous domains of a polymer change from a brittle vitreous state to a solid deformable or ductile state at atmospheric pressure. In other words, the Tg corresponds to the temperature where the onset of segmental motion in the chains of the polymer occurs. When an amorphous or semicrystalline polymer is exposed to an increasing temperature, the coefficient of expansion and the heat capacity of the polymer both increase as the temperature is raised, indicating increased molecular motion. As the temperature is raised, the actual molecular volume in the sample remains constant, and so a higher coefficient of expansion points to an increase in free volume associated with the system and therefore increases freedom for the molecules to move. The increasing heat capacity corresponds to an increase in heat dissipation through movement. Tg of a given polymer can be dependent on the heating rate and can be influenced by the thermal history of the polymer. Furthermore, the chemical structure of the polymer heavily influences the glass transition by affecting mobility.
Other potential problems with polymeric stents include creep, stress relaxation, and physical aging. Creep refers to the gradual deformation that occurs in a polymeric construct subjected to an applied load. It is believed that the delayed response of polymer chains to stress during deformation causes creep behavior. Creep occurs even when the applied load is constant. Creep can cause an expanded stent to retract radially inward, reducing the effectiveness of a stent in maintaining desired vascular patency. The rate at which polymers creep depends not only on the load, but also on temperature. In general, a loaded construct creeps faster at higher temperatures.
Stress relaxation is also a consequence of delayed molecular motions as in creep. Contrary to creep, however, which is experienced when the load is constant, stress relaxation occurs when deformation (or strain) is constant and is manifested by a reduction in the force (stress) required to maintain a constant deformation
Physical aging, as used herein, refers to densification in the amorphous regions of a semi-crystalline polymer. Physical aging of semi-crystalline polymers that have glass transition temperatures (Tg) above their normal storage temperature, which, for the purposes of this invention is room temperature, i.e., from about 15° C. to about 35° C., occurs primarily through the phenomenon known as densification. Densification occurs when polymer chains rearrange in order to move from a non-equilibrium state to an equilibrium state. The reordering of polymer chains tends to increase the modulus of the polymer resulting in a brittle or more brittle polymer.
Thus, physical aging results in an increase in brittleness of a polymer which can result in cracking of struts upon crimping and deployment. Since physical aging results from densification of amorphous regions of a polymer, an increase in crystallinity can reduce or inhibit physical aging.
However, it is well known by those skilled in the art that the mechanical properties of a polymer can be modified through various processing techniques, such as by applying stress to a polymer. James L. White and Joseph E. Spruiell, Polymer and Engineering Science, 1981, Vol. 21, No. 13. The application of stress can induce molecular orientation along the direction of stress which can modify mechanical properties along the direction of applied stress. For example, strength and modulus are some of the important properties that depend upon orientation of polymer chains in a polymer. Molecular orientation refers to the relative orientation of polymer chains along a longitudinal or covalent axis of the polymer chains.
A polymer may be completely amorphous, partially crystalline, or almost completely crystalline. A partially crystalline polymer includes crystalline regions separated by amorphous regions. The crystalline regions do not necessarily have the same or similar orientation of polymer chains. However, a high degree of orientation of crystallites may be induced by applying stress to a semi-crystalline polymer. The stress may also induce orientation in the amorphous regions. An oriented amorphous region also tends to have high strength and high modulus along an axis of alignment of polymer chains. Additionally, for some polymers under some conditions, induced alignment in an amorphous polymer may be accompanied by crystallization of the amorphous polymer into an ordered structure. This is known as stress induced crystallization.
As indicated above, due to the magnitude and directions of stresses imposed on a stent during use, it is important for the mechanical stability of the stent to have suitable mechanical properties, such as strength and modulus in both the axial and circumferential directions. Therefore, it can be advantageous to modify the mechanical properties of a tube, to be used in the fabrication of a stent, by induced orientation from applied stress in the axial direction, circumferential direction, or both. Since highly oriented regions in polymers tend to be associated with higher strength and modulus, it may be desirable to incorporate processes that induce alignment of polymer chains along one or more preferred axes or directions into fabrication of stents.
In keeping with the invention shown in
In another embodiment as shown in
In
In another embodiment as shown in
While the invention has been illustrated and described herein in terms of its use as an intravascular stent for treating coronary arteries, it will be apparent to those skilled in the art that the stent can be used in other instances such as in treating peripheral vessels. Other modifications and improvements may be made without departing from the scope of the invention.
Other modifications and improvements can be made to the invention without departing from the scope thereof.
Number | Name | Date | Kind |
---|---|---|---|
2070073 | Walton | Feb 1937 | A |
2701559 | Cooper | Feb 1955 | A |
2854982 | Pagano | Oct 1958 | A |
2854983 | Baskin | Oct 1958 | A |
3105492 | Jeckel | Oct 1963 | A |
3155095 | Brown | Nov 1964 | A |
3284762 | Kompanek | Nov 1966 | A |
3334629 | Cohn | Aug 1967 | A |
3420142 | Gale et al. | Jan 1969 | A |
3526005 | Bokros et al. | Sep 1970 | A |
3540431 | Mobin-Uddin | Nov 1970 | A |
3562820 | Braun | Feb 1971 | A |
3599641 | Sheridan | Aug 1971 | A |
3657744 | Ersek | Apr 1972 | A |
3713175 | Weisman | Jan 1973 | A |
3714671 | Goodenough et al. | Feb 1973 | A |
3774596 | Cook | Nov 1973 | A |
3834394 | Hunter et al. | Sep 1974 | A |
3858441 | Comeau | Jan 1975 | A |
3868956 | Alfidi et al. | Mar 1975 | A |
3874388 | King | Apr 1975 | A |
3882845 | Bucalo | May 1975 | A |
3889685 | Miller, Jr. et al. | Jun 1975 | A |
3893344 | Dantlgraber et al. | Jul 1975 | A |
3894974 | Hunter | Jul 1975 | A |
3952747 | Kimmell, Jr. | Apr 1976 | A |
3968800 | Vilasi | Jul 1976 | A |
3993078 | Bergentz et al. | Nov 1976 | A |
4038702 | Sawyer | Aug 1977 | A |
4047252 | Liebig et al. | Sep 1977 | A |
4056854 | Boretos et al. | Nov 1977 | A |
4061134 | Samuels et al. | Dec 1977 | A |
4065816 | Sawyer | Jan 1978 | A |
4076285 | Martinez | Feb 1978 | A |
4080706 | Heilman et al. | Mar 1978 | A |
4105022 | Antoshkiw et al. | Aug 1978 | A |
4106129 | Carpentier et al. | Aug 1978 | A |
4130904 | Whalen | Dec 1978 | A |
4140126 | Choudhury | Feb 1979 | A |
4159719 | Haerr | Jul 1979 | A |
4183102 | Guiset | Jan 1980 | A |
4190909 | Ablaza | Mar 1980 | A |
4195637 | Gleichner et al. | Apr 1980 | A |
4198982 | Fortner et al. | Apr 1980 | A |
4214587 | Sakura | Jul 1980 | A |
RE30434 | Davis | Nov 1980 | E |
4264419 | Pryor | Apr 1981 | A |
4276132 | Fettel et al. | Jun 1981 | A |
4295464 | Shihata | Oct 1981 | A |
4299226 | Banka | Nov 1981 | A |
4300244 | Bokros | Nov 1981 | A |
4313231 | Koyamada | Feb 1982 | A |
4319363 | Ketharanathan | Mar 1982 | A |
4323071 | Simpson et al. | Apr 1982 | A |
4323994 | Coogler | Apr 1982 | A |
4328811 | Fogarty | May 1982 | A |
4338942 | Fogarty | Jul 1982 | A |
4340046 | Cox | Jul 1982 | A |
4343048 | Ross et al. | Aug 1982 | A |
4343049 | Fettel et al. | Aug 1982 | A |
4387952 | Slusher | Jun 1983 | A |
4390599 | Broyles | Jun 1983 | A |
4402307 | Hanson et al. | Sep 1983 | A |
4403612 | Fogarty | Sep 1983 | A |
4448195 | Leveen et al. | May 1984 | A |
4479497 | Fogarty et al. | Oct 1984 | A |
4483340 | Fogarty et al. | Nov 1984 | A |
4493711 | Chin et al. | Jan 1985 | A |
4494531 | Gianturco | Jan 1985 | A |
4503569 | Dotter | Mar 1985 | A |
4504354 | George et al. | Mar 1985 | A |
4512338 | Balko et al. | Apr 1985 | A |
4516972 | Samson | May 1985 | A |
4531933 | Norton et al. | Jul 1985 | A |
4550447 | Seiler, Jr. et al. | Nov 1985 | A |
4553545 | Maass et al. | Nov 1985 | A |
4560374 | Hammerslag | Dec 1985 | A |
4562596 | Kornberg | Jan 1986 | A |
4572186 | Gould et al. | Feb 1986 | A |
4577631 | Kreamer | Mar 1986 | A |
4580568 | Gianturco | Apr 1986 | A |
4586505 | Sisson et al. | May 1986 | A |
4604762 | Robinson | Aug 1986 | A |
4616652 | Simpson | Oct 1986 | A |
4617932 | Kornberg | Oct 1986 | A |
4619246 | Molgaard-Nielsen et al. | Oct 1986 | A |
4619261 | Guerriero | Oct 1986 | A |
4641653 | Rockey | Feb 1987 | A |
4643184 | Mobin-Uddin | Feb 1987 | A |
4647416 | Seiler, Jr. et al. | Mar 1987 | A |
4649922 | Wiktor | Mar 1987 | A |
4650466 | Luther | Mar 1987 | A |
4655771 | Wallsten | Apr 1987 | A |
4660559 | McGregor et al. | Apr 1987 | A |
4660560 | Klein | Apr 1987 | A |
4665918 | Garza et al. | May 1987 | A |
4670734 | Caddock | Jun 1987 | A |
4673409 | Van Kampen | Jun 1987 | A |
4676241 | Webb et al. | Jun 1987 | A |
4680031 | Alonso | Jul 1987 | A |
4681110 | Wiktor | Jul 1987 | A |
4699611 | Bowden | Oct 1987 | A |
4704126 | Baswell et al. | Nov 1987 | A |
4705517 | Dipisa, Jr. | Nov 1987 | A |
4706671 | Weinrib | Nov 1987 | A |
4710181 | Fuqua | Dec 1987 | A |
4723549 | Wholey et al. | Feb 1988 | A |
4731054 | Billeter et al. | Mar 1988 | A |
4733665 | Palmaz | Mar 1988 | A |
4739762 | Palmaz | Apr 1988 | A |
4740207 | Kreamer | Apr 1988 | A |
4748982 | Horzewski et al. | Jun 1988 | A |
4760849 | Kropf | Aug 1988 | A |
4762128 | Rosenbluth | Aug 1988 | A |
4767418 | Deininger et al. | Aug 1988 | A |
4768507 | Fischell et al. | Sep 1988 | A |
4771773 | Kropf | Sep 1988 | A |
4771777 | Horzewski et al. | Sep 1988 | A |
4775426 | Murley et al. | Oct 1988 | A |
4776337 | Palmaz | Oct 1988 | A |
4787899 | Lazarus | Nov 1988 | A |
4793348 | Palmaz | Dec 1988 | A |
4794928 | Kletschka | Jan 1989 | A |
4795458 | Regan | Jan 1989 | A |
4800882 | Gianturco | Jan 1989 | A |
4813925 | Anderson, Jr. et al. | Mar 1989 | A |
4823814 | Drogendijk et al. | Apr 1989 | A |
4830003 | Wolff et al. | May 1989 | A |
4842575 | Hoffman, Jr. et al. | Jun 1989 | A |
4848343 | Wallsten et al. | Jul 1989 | A |
4856516 | Hillstead | Aug 1989 | A |
4869714 | Deininger et al. | Sep 1989 | A |
4870966 | Dellon et al. | Oct 1989 | A |
4875480 | Imbert | Oct 1989 | A |
4877030 | Beck et al. | Oct 1989 | A |
4878906 | Lindemann et al. | Nov 1989 | A |
4886062 | Wiktor | Dec 1989 | A |
4887997 | Okada | Dec 1989 | A |
4892539 | Koch | Jan 1990 | A |
4892541 | Alonso | Jan 1990 | A |
4893623 | Rosenbluth | Jan 1990 | A |
4902289 | Yannas | Feb 1990 | A |
4907336 | Gianturco et al. | Mar 1990 | A |
4913141 | Hillstead | Apr 1990 | A |
4921479 | Grayzel | May 1990 | A |
4922905 | Strecker | May 1990 | A |
4923464 | Dipisa, Jr. | May 1990 | A |
4943346 | Mattelin | Jul 1990 | A |
4950227 | Savin et al. | Aug 1990 | A |
4954126 | Wallsten | Sep 1990 | A |
4963022 | Sommargren | Oct 1990 | A |
4969458 | Wiktor | Nov 1990 | A |
4969890 | Sugita et al. | Nov 1990 | A |
4986831 | King et al. | Jan 1991 | A |
4988356 | Crittenden et al. | Jan 1991 | A |
4990155 | Wilkoff | Feb 1991 | A |
4994032 | Sugiyama et al. | Feb 1991 | A |
4994071 | MacGregor | Feb 1991 | A |
4994077 | Dobben | Feb 1991 | A |
4998539 | Delsanti | Mar 1991 | A |
4998923 | Samson et al. | Mar 1991 | A |
5002560 | Machold et al. | Mar 1991 | A |
5007926 | Derbyshire | Apr 1991 | A |
5015253 | MacGregor | May 1991 | A |
5019085 | Hillstead | May 1991 | A |
5019090 | Pinchuk | May 1991 | A |
5026377 | Burton et al. | Jun 1991 | A |
5034001 | Garrison et al. | Jul 1991 | A |
5035706 | Giantureo et al. | Jul 1991 | A |
5037377 | Alonso | Aug 1991 | A |
5037392 | Hillstead | Aug 1991 | A |
5037427 | Harada et al. | Aug 1991 | A |
5041126 | Gianturco | Aug 1991 | A |
5059211 | Stack et al. | Oct 1991 | A |
5061273 | Yock | Oct 1991 | A |
5061275 | Wallsten et al. | Oct 1991 | A |
5062829 | Pryor et al. | Nov 1991 | A |
5064435 | Porter | Nov 1991 | A |
5071407 | Termin et al. | Dec 1991 | A |
5073694 | Tessier et al. | Dec 1991 | A |
5078720 | Burton et al. | Jan 1992 | A |
5078726 | Kreamer | Jan 1992 | A |
5078736 | Behl | Jan 1992 | A |
5084065 | Weldon et al. | Jan 1992 | A |
5089005 | Harada | Feb 1992 | A |
5089006 | Stiles | Feb 1992 | A |
5092877 | Pinchuk | Mar 1992 | A |
5100429 | Sinofsky et al. | Mar 1992 | A |
5102417 | Palmaz | Apr 1992 | A |
5104399 | Lazarus | Apr 1992 | A |
5104404 | Wolff | Apr 1992 | A |
5108416 | Ryan et al. | Apr 1992 | A |
5108417 | Sawyer | Apr 1992 | A |
5116318 | Hillstead | May 1992 | A |
5116360 | Pinchuk et al. | May 1992 | A |
5116365 | Hillstead | May 1992 | A |
5122154 | Rhodes | Jun 1992 | A |
5123917 | Lee | Jun 1992 | A |
5133732 | Wiktor | Jul 1992 | A |
5135536 | Hillstead | Aug 1992 | A |
5158548 | Lau et al. | Oct 1992 | A |
5161547 | Tower | Nov 1992 | A |
5163951 | Pinchuk et al. | Nov 1992 | A |
5163952 | Froix | Nov 1992 | A |
5163958 | Pinchuk | Nov 1992 | A |
5171262 | MacGregor | Dec 1992 | A |
5180368 | Garrison | Jan 1993 | A |
5183085 | Timmermans | Feb 1993 | A |
5192297 | Hull | Mar 1993 | A |
5192307 | Wall | Mar 1993 | A |
5192311 | King et al. | Mar 1993 | A |
5195984 | Schatz | Mar 1993 | A |
5197978 | Hess | Mar 1993 | A |
5201901 | Harada et al. | Apr 1993 | A |
5217482 | Keith | Jun 1993 | A |
5222971 | Willard et al. | Jun 1993 | A |
RE34327 | Kreamer | Jul 1993 | E |
5226913 | Pinchuk | Jul 1993 | A |
5234456 | Silvestrini | Aug 1993 | A |
5236447 | Kubo et al. | Aug 1993 | A |
5242394 | Tremulis | Sep 1993 | A |
5242399 | Lau et al. | Sep 1993 | A |
5242452 | Inoue | Sep 1993 | A |
5266073 | Wall | Nov 1993 | A |
5275622 | Lazarus et al. | Jan 1994 | A |
5282823 | Schwartz et al. | Feb 1994 | A |
5282824 | Gianturco | Feb 1994 | A |
5282848 | Schmitt | Feb 1994 | A |
5290295 | Querals et al. | Mar 1994 | A |
5290305 | Inoue | Mar 1994 | A |
5292331 | Boneau | Mar 1994 | A |
5304200 | Spaulding | Apr 1994 | A |
5306286 | Stack et al. | Apr 1994 | A |
5314444 | Gianturco | May 1994 | A |
5314472 | Fontaine | May 1994 | A |
5330500 | Song | Jul 1994 | A |
5342348 | Kaplan | Aug 1994 | A |
5344426 | Lau et al. | Sep 1994 | A |
5354308 | Simon et al. | Oct 1994 | A |
5354309 | Schnepp-Pesch et al. | Oct 1994 | A |
5356433 | Rowland et al. | Oct 1994 | A |
5360401 | Turnland et al. | Nov 1994 | A |
5368566 | Crocker | Nov 1994 | A |
5372600 | Beyar et al. | Dec 1994 | A |
5378239 | Termin et al. | Jan 1995 | A |
5382261 | Palmaz | Jan 1995 | A |
5383892 | Cardon et al. | Jan 1995 | A |
5397345 | Lazarus | Mar 1995 | A |
5405378 | Strecker | Apr 1995 | A |
5411552 | Andersen et al. | May 1995 | A |
5421955 | Lau et al. | Jun 1995 | A |
5423745 | Todd et al. | Jun 1995 | A |
5423885 | Williams | Jun 1995 | A |
5443496 | Schwartz et al. | Aug 1995 | A |
5445646 | Euteneuer et al. | Aug 1995 | A |
5449373 | Pinchasik et al. | Sep 1995 | A |
5456694 | Marin et al. | Oct 1995 | A |
5458615 | Klemm et al. | Oct 1995 | A |
5476476 | Hillstead | Dec 1995 | A |
5484449 | Amundson et al. | Jan 1996 | A |
5507767 | Maeda et al. | Apr 1996 | A |
5507768 | Lau et al. | Apr 1996 | A |
5507771 | Gianturco | Apr 1996 | A |
5514154 | Lau et al. | May 1996 | A |
5527336 | Rosenbluth et al. | Jun 1996 | A |
5545132 | Fagan | Aug 1996 | A |
5549635 | Solar | Aug 1996 | A |
5549663 | Cottone, Jr. | Aug 1996 | A |
5554181 | Das | Sep 1996 | A |
5556413 | Lam | Sep 1996 | A |
5562728 | Lazarus et al. | Oct 1996 | A |
5569295 | Lam | Oct 1996 | A |
5571135 | Fraser et al. | Nov 1996 | A |
5591197 | Orth et al. | Jan 1997 | A |
5591198 | Boyle et al. | Jan 1997 | A |
5603721 | Lau et al. | Feb 1997 | A |
5618299 | Khosravi et al. | Apr 1997 | A |
5618301 | Hauenstein et al. | Apr 1997 | A |
5626604 | Cottone | May 1997 | A |
5653690 | Booth et al. | Aug 1997 | A |
5653691 | Rupp et al. | Aug 1997 | A |
5653727 | Wiktor | Aug 1997 | A |
5669936 | Lazarus | Sep 1997 | A |
5674278 | Boneau | Oct 1997 | A |
5707386 | Schnepp-Pesch et al. | Jan 1998 | A |
5716396 | Williams, Jr. | Feb 1998 | A |
5718713 | Frantzen | Feb 1998 | A |
5720726 | Marcadis et al. | Feb 1998 | A |
5725570 | Heath | Mar 1998 | A |
5728158 | Lau et al. | Mar 1998 | A |
5733303 | Israel et al. | Mar 1998 | A |
5733325 | Robinson et al. | Mar 1998 | A |
5735893 | Lau et al. | Apr 1998 | A |
5755771 | Penn et al. | May 1998 | A |
5755776 | Al-Saadon | May 1998 | A |
5759192 | Saunders | Jun 1998 | A |
5766238 | Lau et al. | Jun 1998 | A |
5776161 | Globerman | Jul 1998 | A |
5780807 | Saunders | Jul 1998 | A |
5782855 | Lau et al. | Jul 1998 | A |
5800509 | Boneau | Sep 1998 | A |
5800521 | Orth | Sep 1998 | A |
5800526 | Anderson et al. | Sep 1998 | A |
5810871 | Tuckey et al. | Sep 1998 | A |
5817152 | Birdsall et al. | Oct 1998 | A |
5830217 | Ryan | Nov 1998 | A |
5833699 | Chuter | Nov 1998 | A |
5836964 | Richter et al. | Nov 1998 | A |
5836965 | Jendersee et al. | Nov 1998 | A |
5843120 | Israel et al. | Dec 1998 | A |
5843164 | Frantzen et al. | Dec 1998 | A |
5843175 | Frantzen | Dec 1998 | A |
5868782 | Frantzen | Feb 1999 | A |
5879381 | Moriuchi et al. | Mar 1999 | A |
5879382 | Boneau | Mar 1999 | A |
5891190 | Boneau | Apr 1999 | A |
5893852 | Morales | Apr 1999 | A |
5902332 | Schatz | May 1999 | A |
5911732 | Hojeibane | Jun 1999 | A |
5913897 | Corso, Jr. et al. | Jun 1999 | A |
5925061 | Ogi et al. | Jul 1999 | A |
5935162 | Dang | Aug 1999 | A |
5972018 | Israel et al. | Oct 1999 | A |
5980553 | Gray et al. | Nov 1999 | A |
5984964 | Roberts et al. | Nov 1999 | A |
5997468 | Wolff et al. | Dec 1999 | A |
6030413 | Lazarus | Feb 2000 | A |
6056776 | Lau et al. | May 2000 | A |
6066167 | Lau et al. | May 2000 | A |
6066168 | Lau et al. | May 2000 | A |
6146358 | Rowe | Nov 2000 | A |
6309412 | Lau et al. | Oct 2001 | B1 |
6344053 | Boneau | Feb 2002 | B1 |
6432133 | Lau et al. | Aug 2002 | B1 |
6485511 | Lau et al. | Nov 2002 | B2 |
6511504 | Lau et al. | Jan 2003 | B1 |
20040133271 | Jang | Jul 2004 | A1 |
20110238157 | Li et al. | Sep 2011 | A1 |
20120065724 | Jang | Mar 2012 | A1 |
Number | Date | Country |
---|---|---|
1477137 | Nov 2004 | EP |
2017042329 | Mar 2017 | WO |
WO-2017042329 | Mar 2017 | WO |
Entry |
---|
WO2017042329A1—Translation (Year: 2017). |
International Search Report, ISA/US dated May 8, 2019, pp. 1-2. |
Number | Date | Country | |
---|---|---|---|
20190314174 A1 | Oct 2019 | US |